AtaiBeckley: Anxiety Drug Cuts Social Phobia Symptoms By 38%

by | Apr 22, 2026 | General

AtaiBeckley Inc. (NASDAQ:ATAI) shares are up during Wednesday’s premarket session as the company announced expanded Phase 2a results for EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder.

The clinical-stage biotechnology company is focused on developing rapid-acting, durable, and convenient mental health treatments.

EMP-01 Shows Symptom Reduction And Safety Profile

AtaiBeckley reported that EMP-01 achieved a 38% reduction in patient-reported social phobia symptoms compared to a 15% reduction in the placebo group, alongside a favorable safety profile with no severe adverse events.

EMP-01 demonstrated a large, clinically meaningful improvement of −25.9‑points (32% reduction vs 14% on placebo) in real-world behavioral avoidance

The New York-based company also reported:

  • Clinician-assessed improvement: 49% of patients were CGI-I responders at Day 43 vs. 15% on placebo (NNT=2.95), indicating a materially higher rate of clinically meaningful improvement based on overall symptom severity and functioning.
  • Patient-reported improvement: 49% achieved PGI-C response vs. 12% on placebo (NNT=2.72), showing patients recognized clear, meaningful benefits in daily life, consistent with clinician-assessed outcomes.

AtaiBeckley Earlier Topline Data Reinforces Findings

Topline data released in February showed that 49% of patients receiving EMP-01 were rated as “very much improved” or “much improved,” compared to only 15% in the placebo group, indicating a clinically meaningful improvement.

AtaiBeckley Depression Drug Shows Sustained Antidepressant Response

In April, AtaiBeckley shared promising Phase 2a results for its treatment-resistant depression drug, BPL-003.

The company reported a 66.7% antidepressant response rate at Day 2.

AtaiBeckley announced that a single intranasal dose of BPL-003 achieved significant reductions in MADRS scores among participants with treatment-resistant depression, with 83% of patients maintaining a response at Week 12.

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $16.33. Recent analyst moves include:

  • Canaccord Genuity: Buy (Raises Target to $15.00) (April 20)
  • Guggenheim: Buy (Raises Target to $16.00) (April 17)
  • Deutsche Bank: Initiated with Buy (Target $12.00) (March 27)

ATAI Stock Price Activity: AtaiBeckley shares were up 1.64% at $4.95 during premarket trading on Wednesday, according to Benzinga Pro data.

Image via Shutterstock